Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07524738 · ClinicalTrials.gov registry record · Phase 3
Telemedicine XR-B for Individuals in Jail
A Phase 3 study, sponsored by Friends Research Institute.
- Active
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
NCT07524738 is a Phase 3 study that is active but no longer recruiting, run by Friends Research Institute. The registered enrollment target is 30 participants.
The verdict
NCT07524738, a Phase 3 study, is active but no longer recruiting, sponsored by Friends Research Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study is an open label pilot study of 30 incarcerated men and women receiving sublingual buprenorphine (SL-B) in jail who will voluntarily switch to extended-release buprenorphine (BRIXADI) using telemedicine prior to release. Individuals will receive weekly XR-B and at least one monthly XR-B injection prior to release. Individuals will be linked to a community treatment provider where they will continue their treatment (buprenorphine) post-release. Participants will be assessed at 1,2-, and 3-months post release
Interventions
- DRUG Extended Release Buprenorphine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-06-01 |
| Est. Completion | 2026-09-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07524738
The ClinicalTrials.gov registry entry for NCT07524738 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Friends Research Institute, which has 41 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Extended Release Buprenorphine is the first listed.
NCT07524738 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07524738 about?
NCT07524738 is a clinical study titled "Telemedicine XR-B for Individuals in Jail". This study is an open label pilot study of 30 incarcerated men and women receiving sublingual buprenorphine (SL-B) in jail who will voluntarily switch to extended-release buprenorphine (BRIXADI) using telemedicine prior to release. Individuals will receive weekly XR-B and at least one monthly XR-B i...
What is the current status of trial NCT07524738?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2025-06-01. Estimated completion is 2026-09-01.
What interventions are being tested in trial NCT07524738?
The interventions under investigation include: Extended Release Buprenorphine (DRUG).
Who is sponsoring clinical trial NCT07524738?
This trial is sponsored by Friends Research Institute, which has 41 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.